Delhi HC on October, 7 has restrained Indian firm Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs Zita and Zita-Met, as it has infringed patent of the American drug company Merck Sharp and Dohme (MSD).Allowing the injunction Justice A K Pathak said and added that MSD shall be entitled to actual cost of the proceedings.Glenmark is restrained by decree of permanent injunction from making using, selling, distributing, advertising, exporting, offering for sale or dealing in Sitagliptin phosphate monohydrate or any other salt of Sitagliptin in any form, alone or in combination with any other drug thereby infringing patent of plaintiff (MSD).MSD in its plea had sought injunction against Glenmark alleging that the Indian pharma company had violated its IPR over its anti-diabetes medicines, Januvia and Janumet, by coming out with their own drugs containing the same salts.